Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 17 Jun 2013 |
| Grant of Warrants to an Employee in Genmab | 12 Jun 2013 |
| Major shareholder announcement | 11 Jun 2013 |
| Teprotumumab Restarts Clinical Development in New Indication | 11 Jun 2013 |
| Genmab Launches Sponsored Level 1 American Depositary Receipt (ADR) Program | 31 May 2013 |